Zydus bags USFDA nod for Venlafaxine ER Tablets, Pregabalin ER Tablets
Ahmedabad: Drugmaker, Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited), has recently announced that the company has received final approval from the United States Food and Drug Administration (USFDA) to market Venlafaxine Extended-Release Tablets, USP 37.5 mg, 75 mg, 150 mg and 225 mg. USRLD: Venlafaxine Hydrochloride Extended-Release Tablets.
The company also received the final approval from USFDA to market Pregabalin Extended-Release Tablets, USP 82.5 mg, 165 mg and 330 mg. USRLD: Lyrica CR.
Venlafaxine is used to treat depression, anxiety, panic attacks and social anxiety disorder. It is expected to improve mood and energy levels in patients. The medication is also expected to decrease fear, anxiety, unwanted thoughts and the number of panic attacks. The drug will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ, India.
Venlafaxine Extended-Release tablets had annual sales of USD 46 mn in the United States according to IQVIA MAT July 2022.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.